Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients

L Bergui, I Ricca, S Campana, A Pileri - Medical Oncology, 2000 - Springer
Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …
被引用次数：44 相关文章

Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients.

M Ladetto, L Bergui, I Ricca, S Campana… - Medical Oncology …, 2000 - europepmc.org
Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …

Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients.

M Ladetto, L Bergui, I Ricca, S Campana, A Pileri… - MEDICAL …, 2000 - iris.unito.it
Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …

Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients

M Ladetto, L Bergui, I Ricca, S Campana… - MEDICAL …, 2000 - iris.uniupo.it
Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …

Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients

M Ladetto, L Bergui, I Ricca, S Campana… - Medical …, 2000 - search.proquest.com
Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …

Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients

M Ladetto, L Bergui, I Ricca, S Campana… - Medical …, 2000 - research.uniupo.it
Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …

[引用][C] Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients

M LADETTO, L BERGUI, I RICCA… - Medical oncology …, 2000 - pascal-francis.inist.fr
Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of
peripheral blood lymphocytes in chronic lymphocytic leukaemia patients CNRS Inist Pascal-Francis …

Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients

M Ladetto, L Bergui, I Ricca… - Medical oncology …, 2000 - pubmed.ncbi.nlm.nih.gov
Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …

Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients

M Ladetto, L Bergui, I Ricca, S Campana… - Medical …, 2000 - research.uniupo.it
Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …

Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients.

M Ladetto, L Bergui, I Ricca, S Campana… - Medical …, 2000 - search.proquest.com
Rituximab has been recently proposed as an effective non-chemotherapeutic option for
patients with follicle centre lymphoma (FCL). However, less is known on its role in chronic …